336 In conclusion, this present study demonstrated that except Hcy,
337 the cardiovascular risk factors and some other variables had no effect
338 on ADMA levels. After adjustments of demographic, clinical and labo-
339 ratory variables, no effect was observed on the relationship between
340 Hcy and ADMA. These results suggest that plasma Hcy level is the
341 major factor which affects plasma ADMA concentrations in patients
342 with CAD and interventions for lowering homocysteine concentra-
343 tions may also induce a decrease in ADMA levels.
344 Conﬂict of interest
345 Authors declare no conﬂict of interest.
349 This work was supported by the Ege University Research Projects,
350 Izmir, Turkey.
351 Author contributions
352 Ozben O. Isiklar: conduct and design of the study, data collection
353 and analysis.
354 Burcu Barutcuoglu : data interpretation and manuscript writing.
355 Ceyda Kabaroglu: data interpretation and manuscript writing
356 Isil Mutaf: conduct and design of the study, data analysis and in-
357 terpretation, manuscript writing
358 Dilek Ozmen: data interpretation and manuscript writing
359 Oya Bayindir: conduct and design of the study
360 Mehdi Zoghi: coronary angiography evaluations and patient
362 Hatice Uluer: statistical analysis
364  D'Angelo A, Selhub J. Homocysteine and thrombotic disease. Blood 1997;90(1):
366  Matetzky S, Freimark D, Ben-Ami S, et al. Association of elevated homocysteine
367 levels with a higher risk of recurrent coronary events and mortality in patients
368 with acute myocardial infarction. Arch Intern Med 2003;163(16):1933–7.
369  Tyagi N, Sedoris KC, Steed M, et al. Mechanisms of homocysteine-induced oxida-
370 tive stress. Am J Physiol Heart Circ Physiol 2005;289(6):H2649–56.
371  Stühlinger MC, Oka RK, Graf EE, et al. Endothelial dysfunction induced by hyper-
372 homocyst(e)inemia: role of asymmetric dimethylarginine. Circulation 2003;108(8):
374  Stühlinger MC, Stanger O. Asymmetric dimethyl-L-arginine (ADMA): a possible
375 link between homocyst(e)ine and endothelial dysfunction. Curr Drug Metab
377  Böger RH, Sydow K, Borlak J, et al. LDL cholesterol upregulates synthesis of
378 asymmetrical di methylarginine in human endothelial cells: involvement of
379 S-adenosylmethionine-dependent methyltransferases. Circ Res 2000;87(2):99–105.
380  Dayal S, Rodionov RN, Arning E, et al. Tissue-speciﬁc downregulation of
381 dimethylarginine dimethylaminohydrolase in hyperhomocysteinemia. Am J
382 Physiol Heart Circ Physiol 2008;295(2):H816–25.
383  Leiper J, Vallance P. Biological signiﬁcance of endogenous methylarginines that in-
384 hibit nitric oxide synthases. Cardiovasc Res 1999;43:542–8.
385  Boger RH, Bode-Boger SM, Sydow K, et al. Plasma concentration of asymmetric
386 dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated
387 in monkeys with hyperhomocyst-(e)inemia or hypercholesterolemia. Arterioscler
388 Thromb Vasc Biol 2000;20(6):1557–64.
389  Zinellu A, Sotgia S, Sca nu B, et al. Determination of protein-incorporated meth-
390 ylated arginine reference values in healthy subjects whole bl ood and evaluation
391 of factors affecting protein methylation. Clin Biochem 2008;41(14 –15):
393  Meinitzer A, Seelhorst U, Wellnitz B, et al. Asymmetrical dimethylarginine inde-
394 pendently predicts total and cardiovascular mortality in individuals with angio-
395 graphic coronary artery disease (The Ludwigshafen Risk and Cardiovascular
396 Health Study). Clin Chem 2007;53(2):273–83.
397  Yoo JH, Lee SC. Elevated levels of plasma homocyst( e)ine and asymmetric
398 dimethylarginine in elderly patients with stroke. Atherosclerosis 2001;158(2):
400  SelleyML.Increased concentrations of homocysteine and asymmetric dimethylarginine
401 and decreased concentrations of nitric oxide in the plasma of patients with Alzheimer's
402 disease. Neurobiol Aging 2003;24(7):903–7.
403  Paroni R, Fermo I, Fiorina P, et al. Determination of asymmetric and symmetric
404 dimethylarginines in plasma of hyperhomocysteinemic subjects. Amino Acids
406 Jonasson TF, Hedner T, Hultberg B, et al. Hyperhomocysteinaemia is not associat-
407ed with increased levels of asymmetric dimethylarginine in patients with
408ischaemic heart disease. Eur J Clin Invest 2003;33:543–9.
409 Doshi S, McDowell I, Goodfellow J, et al. Relationship between S-adenosylmethionine,
410S-adenosylhomocysteine, asymmetric dimethylarginine, and endothelial function in
411healthy human subjects during experimental hyper- and hypohomocysteinemia.
413 Spoelstra-de Man AM, Teerlink T, Brouwer CB, et al. No effect of B vitamins on
414ADMA levels in patients at increased cardiovascular risk. Clin Endocrinol (Oxf)
416 Schmitt B, Wolters M, Kressel G, et al. Effects of combined supplementation with B
417vitamins and antioxidants on plasma levels of asymmetric dimethylarginine
418(ADMA) in subjects with elevated risk for cardiovascular disease. Atherosclerosis
420 Ziegler S, Mittermayer F, Plank C, et al. Homocyst(e)ine-lowering therapy does
421not affect plasma asymmetrical dimethylarginine concentrations in patients
422with peripheral artery disease. J Clin Endocrinol Metab 2005;90:2175–8.
423 Dayal S, Arning E, Bottiglieri T, et al. Cerebral vascular dysfunction mediated by
424superoxide in hyperhomocysteinemic mice. Stroke 2004;35:1957–62.
425 Böger RH, Bode-Böger SM, Szuba A, et al. Asymmetric dimethylarginine (ADMA):
426a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia.
428 Surdacki A, Nowicki M, Sandmann J, et al. Reduced urinary excretion of nitric
429oxide metabolites and increased plasma levels of asymmetric dimethylarginine
430in men with essential hypertension. J Cardiovasc Pharmacol 1999;33:652–8.
431 Stühlinger MC, Abbasi F, Chu JW, et al. Relationship between insulin resistance
432and an endogenous nitric oxide synthase inhibitor. J Am Med Assoc 2002;287:
434 Abbasi F, Asagmi T, Cooke JP, et al. Plasma concentrations of asymmetric
435dimethylarginine are increased in patients with type 2 diabetes mellitus. Am J
437 Fleck C, Schweitzer F, Karge E, et al. Serum concentrations of asymmetric (ADMA)
438and symmetric (SDMA) dimethylarginine in patients with chronic kidney dis-
439eases. Clin Chim Acta 2003;336:1–12.
440 Wang J, Sim AS, Wang XL, et al. Relations between plasma asymmetric
441dimethylarginine (ADMA) and risk factors for coronary disease. Atherosclerosis
443 Eid HM, Arnesen H, Hjerkinn EM, et al. Relationship between obesity, smoking, and
444the endogenous nitric oxide synthase inhibitor, asymmetric dimethylarginine. Metab-
446 Katsuki A, Sumida Y, Gabazza EC. Homeostasis Model Assessment is a reliable
447indicator of insulin resistance during follow-up of patients with type 2 diabetes.
448Diabetes Care 2001;24:362–5.
449 Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular
450ﬁltration rate from serum creatinine: a new prediction equation. Modiﬁcation of
451diet in renal disease study group. Ann Intern Med 1999;130(6):461–70.
452 Gensini GG. A more meaningful scoring system for determining the severity of
453coronary heart disease. Am J Cardiol 1983;51:606.
454 Weiss N, Zhang YY, Heydrick S, et al. Overexpression of cellular glutathione per-
455oxidase rescues homocyst(e)ine-induced endothelial dysfunction. Proc Natl
456Acad Sci U S A 2001;98:12503–8.
457 Zinellu A, Sotgia S, Porcu P, et al. Carotid restenosis is associated with plasma
458ADMA concentrations in carotid endarterectomy patients. Clin Chem Lab Med
460 Perna M, Roman MJ, Alpert DR, et al. Relationship of asymmetric dimethylarginine
461and homocysteine to vascular aging in systemic lupus erythematosus patient.
462Arthritis Rheum 2010;62(6):1718–22.
463 Mamatha SN, Nagaraja D, Philip M, et al. Asymmetric dimethylarginine as a risk
464marker for early-onset ischemic stroke in Indian population. Clin Chim Acta
466 Murr C, Meinitzer A, Grammer T, et al. Association between asymmetric
467dimethylarginine and neopterin in patients with and without angiographic coro-
468nary artery disease. Scand J Immunol 2009;70(1):63–7.
469 Ogawa T, Kimoto M, Sasaoka K. Puriﬁcation and properties of a new enzyme, NG,
470NGdimethylarginine dimethylaminohydrolase, from rat kidney. J Biol Chem
472 Stuhlinger MC, Tsao PS, Her JH, et al. Homocysteine impairs the nitric oxide
473synthase pathway: role of asymmetric dimethylarginine. Circulation 2001;104:
475 Leiper J, Murray-Rust J, McDonald N, et al. S-Nitrosylation of dimethylarginine
476dimethylaminohydrolase regulates enzyme activity: further interactions between
477nitric oxide synthase and dimethylarginine dimethylaminohydrolase. Proc Natl
478Acad Sci U S A 2002;99:13527–32.
479 Murray-Rust J, Leiper J, McAlister M, et al. Structural insights into the hydrolysis of cel-
480lular nitric oxide synthase inhibitors by dimethylarginine dimethylaminohydr olase.
481Nat Struct Biol 2001;8:679–83.
482 Bae SW, Stuhlinger MC, Yoo HS, et al. Plasma asymmetric dimethylarginine con-
483centrations in newly diagnosed patients with acute myocardial infarction or un-
484stable angina pectoris during two weeks of medical treatment. Am J Cardiol
486 Al Banchaabouchi M, Marescau B, Possemiers I, et al. NG, NG-dimethylarginine
487and NG, NG-dimethylarginine in renal insufﬁciency. Pﬂugers Arch 2000;439(5):
489 Kielstein JT, Boger RH, Bode-Boger SM, et al. Low dialysance of asymmetric
490dimethylarginine (ADMA) — in vivo and in vitro evidence of signiﬁcant protein
491binding. Clin Nephrol 2004;62(4):295–300.
5Ö.O. Işıklar et al. / Clinical Biochemistry xxx (2012) xxx–xxx
Please cite this article as: Işıklar ÖO, et al, Do cardiac risk factors affect the homocysteine and asymmetric dimethylarginine relationship in
patients with coronary artery diseases?, Clin Biochem (2012), doi:10.1016/j.clinbiochem.2012.06.024